je.st
news
Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients
2015-06-02 17:19:37| Logistics - Topix.net
OncoGenex Pharmaceuticals, Inc. announced that results from an exploratory analysis of the Phase 2 Borealis-1 trial showed that metastatic bladder cancer patients with poor prognostic features benefited from apatorsen 600mg added to first-line chemotherapy compared to chemotherapy alone. Patients in the trial with a Karnofsky Performance Status of 80 percent or less, a common indicator of poor prognosis, experienced a 50 percent reduction in risk of death with the addition of apatorsen therapy .
Tags: added
benefits
cancer
patients
Category:Transportation and Logistics
Latest from this category |
All news |
||||||||||||||||||
|
|||||||||||||||||||